Medicines (Representational image) | ThePrint
Medicines (Representational image) | ThePrint
Text Size:

New Delhi: Researchers at the premier Indian Institute of Technology, Hyderabad, have formulated oral tablets that they say will ensure better and faster treatment of the deadly parasitic disease visceral leishmaniasis, commonly known as kala-azar or black fever.

Kala-azar is a fatal disease caused by the bite of a sandfly; it affects the bone marrow, spleen and liver. At present, the disease is treated through injection-based administration of the drug Amphotericin B but that leads to an uncontrolled release of the drug into a patient’s bloodstream, resulting in high toxicity.

The IIT researchers say their tablets will release Amphotericin B in a sustained and controlled manner over a period of 10 days, which is likely to increase the chances of a patient’s recovery.

The drug uses nanofibres, which are 1,00,000 times thinner than human hair, for the controlled release of drug molecules.

“In order to make controlled-release oral tablets, the drug molecules must be loaded onto a base that dissolves gradually to release the drug over a period of time,” said Dr Chandra Shekhar Sharma, associate professor, creative and advanced research based on nanomaterials (CARBON) laboratory, Department of Chemical Engineering, IIT Hyderabad. Sharma led the research along with professor Saptarshi Majumdar.

“The development of oral, controlled-release tablets for fatal fungal infections and leishmaniasis, will help in better management of the disease burden in the country,” IIT Hyderabad said in a statement Thursday, adding that “the team’s work has been published in the July 2019 issue of the reputed peer-reviewed journal Nano-Structures and Nano-Objects”.

“Many attempts have been made earlier to make oral medication to control the delivery of the drug and bring down costs,” the statement added.

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrint’s future.


Status of kala-azar in India

In India, malaria, dengue and kala-azar are the top three vector-borne diseases.

According to the latest data by the Ministry of Health and Family Welfare, India registered over 5,700 cases of kala-azar in 2017.

Often referred to as a ‘disease of poverty’, the maximum number of cases were found in the economically underprivileged sections of Jharkhand, Bihar, West Bengal and Uttar Pradesh.

India had missed the 2017 deadline set to eliminate the disease. This was blamed on the absence of concrete or pucca houses in most infected areas and the issue was raised with the rural development ministry.

“As the endemic blocks (states) have a majority of houses made of wood, it is very difficult to eliminate the vector as it (the parasite) dwells in the wooden structure and escapes various measures to kill it,” reported The Financial Express last year. “Hence, to stop the transmission of infection, pucca houses need to be built.”

Also read: This parasitic skin disease is scarring one million people every year worldwide


Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And we aren’t even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrint’s future. It will take just a few seconds of your time.

Support Our Journalism

1 Comment Share Your Views


  1. Even miltifosine is found more effective in treatment of this disease, I remember 13 years back when I left my previous laboratory we were working on Phase two clinical trials of Miltifosine and also working on novel bio deliverables with good laboratory level results…. Don’t know what is the current status…. NOW I STOPPED DOING SCIENCE


Please enter your comment!
Please enter your name here